Search Results
Your search for all items matches 34730 pages
Showing 22601 - 22650Study Suggests Benefit of Adjuvant Radiation Therapy but Not Chemotherapy in Some Patients With Merkel Cell Carcinoma
In an analysis of National Cancer Data Base data reported in the Journal of the National Cancer Institute, Shailender Bhatia, MD, of the University of Washington/Fred Hutchinson Cancer Research Center, and colleagues found that adjuvant radiotherapy was associated with a survival benefit in...
Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients
In the HIV-negative population, there is growing evidence suggesting that chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are both associated with the development of non-Hodgkin lymphoma (NHL), although the mechanisms underlying this association remain unclear. The incidence rate of NHL ...
Higher Baseline Metabolic Tumor Volume and Poorer Outcomes in Patients With High Tumor Burden Follicular Lymphoma
In a pooled analysis reported in the Journal of Clinical Oncology, Michel Meignan, MD, PhD, of the Université Paris-Est Créteil, and colleagues found that higher baseline total metabolic tumor volume measured by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography–computed tomography (FDG...
Meta-analysis Identifies New Genetic Variants for Barrett’s Esophagus and Esophageal Adenocarcinoma
As reported in The Lancet Oncology, Puya Gharahkhani, PhD, of QIMR Berghofer Medical Research Institute, Brisbane, Australia, and colleagues identified several new genetic risk variants for the development of Barrett’s esophagus and esophageal adenocarcinoma through a large-scale meta-analysis of...
Two Big 10 Universities Compete in Challenge and Help Raise More Than $5.9 Million for Childhood Cancer Research
The first-ever Wolverine–Badger challenge between C.S. Mott Children’s Hospital at the University of Michigan (Wolverines) and the University of Wisconsin’s American Family Children’s Hospital (Badgers) helped raise more than $5.9 million for pediatric cancer research. An October 1 football game...
Expect Questions About Medical Marijuana
“Whether or not individual professionals support the clinical use of herbal cannabis, all clinicians will encounter patients who elect to use it and therefore need to be prepared to advise them on cannabis-related clinical issues despite limited evidence to guide care,” according to a recently...
When Marijuana Was Legal in the United States
Marijuana, or cannabis, used to be legal in the United States and was “actually listed in the U.S. formulary in 1854,” according to Judith A. Paice, PhD, RN, Director, Cancer Pain Program, Division of Hematology-Oncology at Northwestern University, Feinberg School of Medicine, Chicago. “Many of...
Medical Marijuana: The Topic You Can’t Escape
With reports about new marijuana dispensaries sprouting up as more states approve the legal use of medical marijuana, and patients and family members questioning how to get it, medical marijuana is a “topic you can’t escape,” noted Judith A. Paice, PhD, RN.1 Dr. Paice is Director of the Cancer...
David Cella, PhD, Receives Lienhard Award from National Academy of Medicine
David Cella, PhD, Associate Director for Cancer Prevention and Control Research at the Lurie Cancer Center of Northwestern University, was awarded the Gustav O. Lienhard Award for his pioneering work to measure and apply patient-reported outcomes in health care. The award was presented at the...
The Smartest Guys in the Room
The smartest guys in the room were never from the big energy companies, and they’re not running hedge funds on Wall Street or building the next Facebook. For me, the smartest guys in the room are the selfless men and women who’ve transformed cancer from what was all too often a death sentence to...
Advanced Practitioners Convene for Annual JADPRO Live at APSHO Meeting
The fourth annual JADPRO Live conference was held recently in conjunction with the Annual Meeting of the Advanced Practitioner Society for Hematology and Oncology (APSHO) on November 3–6, 2016, at the Gaylord National Hotel in National Harbor, Maryland. More than 1,100 individuals attended...
2016-2017 Oncology Meetings
NOVEMBER 21st Annual Perspectives in Thoracic OncologyNovember 18-19 • New York, New YorkFor more information:http://imedex.com/perspectives-thoracic-oncology-conference/index.asp Mayo Clinic Angiogenesis and Tumor Microenvironment Symposium: From Translational Research to Clinical Practice...
Resuscitation During Surgery
During the 1890s, aseptic principles were extended only to the operative area of the patient, not the surgeon, although some surgeons did advocate the use of special white or colored uniforms, and hand washing had already been established. In 1895, just 7 years after Arpad Gerster, MD, published...
Enrollment Completed for Phase III ECHELON-2 Clinical Trial Evaluating Front-Line Brentuximab Vedotin in Mature T-Cell Lymphoma
Seattle Genetics, Inc, and Takeda Pharmaceutical Company Limited have announced completion of patient enrollment in the ECHELON-2 clinical trial. ECHELON-2 is a global phase III randomized trial evaluating brentuximab vedotin (Adcetris) as part of a front-line combination chemotherapy regimen in...
ASH Honors Thalia Papayannopoulou, MD, With Wallace H. Coulter Award for Lifetime Achievement in Hematology
The American Society of Hematology (ASH) will recognize Thalia Papayannopoulou, MD, of the University of Washington, Seattle, with the 2016 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Papayannopoulou will be honored for her innovative contributions to cutting-edge areas of ...
David Scadden, MD, to Present the 2016 ASH E. Donnall Thomas Lecture
The American Society of Hematology (ASH) will honor David Scadden, MD, of Massachusetts General Hospital and Harvard Medical School, with the 2016 E. Donnall Thomas Lecture and Prize for his work on the bone marrow hematopoietic microenvironment. This lectureship and prize is named after the late...
Olaratumab in Soft-Tissue Sarcoma
On October 19, 2016, the platelet-derived growth factor receptor alpha (PDGFR-α)-blocking antibody olaratumab (Lartruvo) was granted accelerated approval in combination with doxorubicin for the treatment of soft-tissue sarcoma not amenable to curative treatment with radiotherapy or surgery and...
Let’s Win: Innovative Online Community Offers Guidance to Patients With Pancreatic Cancer and Their Families
Let’s Win is an online community for persons with pancreatic cancer (www.letswinpc.org), but it is far more than a typical support group. Let’s Win propels interested users toward cutting-edge research, based on its founders’ commitment that no patient with pancreatic cancer should settle on the...
Low Vitamin D Levels May Be Linked to Increased Risk of Bladder Cancer
Vitamin D deficiency may be associated with an increased risk of developing bladder cancer, according to a systematic review of seven studies presented at the Society for Endocrinology Annual Conference in Brighton, United Kingdom. Though further clinical studies are needed to confirm the findings, ...
New Blood Test for Colorectal Cancer Recurrence: Twice as Sensitive as CEA Test
In a new report published by Young et al in Cancer Medicine,1 a two-gene circulating tumor DNA (ctDNA) blood test for postsurgical monitoring of colorectal cancer recurrence has been shown to detect twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing, a standard-of-care...
Modified Indication for Erlotinib in Advanced Non–Small Cell Lung Cancer
On October 18, 2016, the indication for erlotinib (Tarceva) in the treatment of non–small cell lung cancer (NSCLC) was modified to limit use to patients with tumors with specific epidermal growth factor receptor (EGFR) mutations in maintenance or second- or greater-line treatment; these mutations...
Lower Risk of All-Cause Mortality in Multiple Myeloma Reported With Treatment at Higher-Volume Facilities
In an analysis of data from the National Cancer Database reported in the Journal of Clinical Oncology, Go et al found a lower risk of all-cause mortality among patients with multiple myeloma treated at higher-volume facilities. Study Details The study included patients diagnosed with multiple...
No Advantage to Adding Seribantumab to Paclitaxel in Platinum-Resistant/Refractory Ovarian Cancer, but Subgroup May Benefit
In a phase II study reported in the Journal of Clinical Oncology, Liu et al found no progression-free survival benefit of adding the anti-HER3 (ErbB3) antibody seribantumab to paclitaxel in unselected patients with advanced platinum-resistant or -refractory ovarian cancer. However, exploratory...
Meeting the Needs of Older Adults With Cancer
I have served as a patient advocate in many different ways since I was diagnosed with breast cancer in October 2000. For many years, my advocacy was focused on issues related to breast cancer. Since 2012, I have also been engaged in identifying and meeting the needs of the rapidly growing...
Suresh S. Ramalingam, MD, Honored With Goizueta Chair for Cancer Research at Winship Cancer Institute
Suresh S. Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University and Assistant Dean for Cancer Research in the Emory School of Medicine, was honored with the Roberto C. Goizueta Distinguished Chair for Cancer Research. The endowment was established to support a key leader...
Kwok-Kin Wong, MD, PhD, to Join NYU Langone as Chief of Hematology and Medical Oncology
The Perlmutter Cancer Center at New York University (NYU) Langone Medical Center has named clinician-scientist Kwok-Kin Wong, MD, PhD, as its new Chief of Hematology and Medical Oncology. His recruitment promises to transform the medical center’s research and clinical programs in lung cancer and...
Fox Chase Cancer Center Designated as a National Pancreas Foundation Center
Fox Chase Cancer Center has been designated as a National Pancreas Foundation Center by the National Pancreas Foundation (NPF), a nonprofit organization that provides hope for those suffering from pancreatic cancer and other pancreas-related diseases. Fox Chase is the only institution in the...
Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy
What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...
Talking to Children With Cancer: Sometimes Less Is More
I still remember the day I met Kensie. It was Valentine’s Day. I had sneaked out of the hospital to get my wife a Valentine’s Day card, taking my place among scores of other husbands and boyfriends in front of the rapidly emptying rack of cards. As I started browsing, my beeper sounded. It was the ...
Diagnosing and Managing Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a common side effect of cancer treatment—the incidence is reported to be as high as 70% in the first month of chemotherapy1—and can cause significant disability in patients. The extent of the neurotoxicity incurred by patients varies depending on the...
CDC Recommends Only Two HPV Shots for Younger Adolescents
The Centers for Disease Control and Prevention (CDC) have recommended that 11- to 12-year-olds receive 2 doses of human papillomavirus (HPV) vaccine at least 6 months apart rather than the previously recommended 3 doses to protect against cancers caused by HPV infections. Teens and young adults who ...
Forging Collaboration Between Children’s and Adult Oncology Groups in Designing Trials for Adolescents and Young Adults
Nonrhabdomyosarcoma soft-tissue sarcomas account for about 5% of all childhood malignancies and are also diagnosed in adolescents and young adults, as well as in older adults, and can require different approaches to treatment based on a patient’s age and stage of disease. These sarcomas comprise...
Dana-Farber Cancer Institute, CPDC at McMaster University Join to Speed Cancer Research With Molecular Probes
Dana-Farber Cancer Institute and the Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, Canada, will work together to create novel molecular probes for noninvasive imaging in cancer research, drug development, and patient care. The two leading...
Cardio-oncology in the Geriatric Patient
As cancer therapies improve and the population as a whole increases, there are rising numbers of elderly patients with cancer. More than half of patients newly diagnosed with cancer are aged 65 years or older.1 In January 2012, it was estimated that more than 8 million cancer survivors were over...
Use Social Media to Stay Up-to-Date on New Patient Materials From Cancer.Net
Encourage your patients to use social media for details on the newest resources available on Cancer.Net. It is easier than ever for patients to get the latest cancer information on their computer or mobile device by subscribing to the Cancer.Net Blog at www.cancer.net/blog or on Cancer.Net’s...
Conquer Cancer Foundation’s International Programs
Did you know the Conquer Cancer Foundation of ASCO (CCF) has provided funding for cancer research in 68 countries? In more than 33 years, over 1,700 grants and awards totaling $105 million have been given out by CCF worldwide. CCF grants and awards support clinical and translational cancer research ...
ASCO Introduces Two New Journals: JCO Precision Oncology and JCO Clinical Cancer Informatics
ASCO is excited to launch two new online-only journals, JCO Precision Oncology (JCO PO) and JCO Clinical Cancer Informatics (JCO CCI). Both journals will be exploring the latest topics in oncology and filling a void for the oncology community. Manuscripts will go through the traditional peer-review ...
ASCO’s Quality Training Program Shifts to a Regional Setting; Applications Now Open for 2017
On October 17, applications opened for ASCO’s 2017 Quality Training Program. For 2017, the program, which began 3 years ago, is shifting its model of in-person sessions at ASCO headquarters in Alexandria, Virginia, to regional settings. The program is designed to train oncology health-care...
Research Community Forum 2016 Annual Meeting: Using Collective Wisdom to Improve Cancer Research
The ASCO Research Community Forum held its 2016 Annual Meeting from September 25–26, at ASCO headquarters in Alexandria, Virginia. Nearly 100 physician investigators and research staff from all types of research sites across the United States attended the meeting. Each year, the ASCO Research...
ASCO Announces Candidates for 2017 Election
Twelve distinguished ASCO members have been selected by the Nominating Committee as candidates for open leadership positions within the Society, including the office of President-Elect, three seats on the Board of Directors, and two seats on the Nominating Committee. Biographical information and...
Interviews With ASCO’s President-Elect Candidates
ASCO Connection: Why do you want to serve as ASCO President? Monica Bertagnolli: Serving as ASCO President is a tremendous personal honor for anyone in the field of oncology. Much more importantly, it is an opportunity to make a meaningful difference by providing a strong voice in the health-care ...
Atezolizumab in Previously Treated Metastatic NSCLC
On October 18, 2016, the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab (Tecentriq) was approved for the treatment of metastatic non–small cell lung cancer (NSCLC) progressing during or following platinum-containing chemotherapy.1,2 Patients with epidermal growth factor receptor ...
CancerLinQ™ Platform Hits Milestone of Having More Than 1 Million Patient Records in System
CancerLinQ LLC, a wholly owned nonprofit of ASCO, announced on October 20, 2016, that more than 1 million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ, representing more than 1,500 oncologists. “We are excited to...
As More Biosimilars Move Toward U.S. Market, Questions Remain About Cost Savings and Uptake by Physicians and Patients
The U.S. Food and Drug Administration (FDA) approved its first biosimilar drug, filgrastim-sndz (Zarxio), in 2015, allowing it to compete with the granulocyte colony-stimulating factor filgrastim (Neupogen) to treat neutropenia in chemotherapy patients. So far, filgrastim-sndz is the only...
Ellen and Gary Davis Immune Monitoring Core Established at Weill Cornell Medicine
With the goal of advancing a powerful cancer treatment strategy that uses immune cells to fight the disease, benefactors Ellen and Gary Davis have made a $2 million gift to Weill Cornell Medicine to drive ongoing research in immunotherapy, the institution announced. This gift will launch the Ellen...
Charles S. Fuchs, MD, MPH, to Lead Yale Cancer Center and Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center (YCC) have announced that Charles S. Fuchs, MD, MPH, will become the new Director and Physician-in-Chief at Smilow Cancer Hospital at Yale New Haven, effective January 1, 2017. Dr. Fuchs will be taking the reins of the Smilow Cancer...
Florida Atlantic University Appoints Phillip M. Boiselle, MD, as Dean of the Charles E. Schmidt College of Medicine
Florida Atlantic University has named Phillip M. Boiselle, MD, as the new Dean of the Charles E. Schmidt College of Medicine. Dr. Boiselle, who currently serves as Associate Dean for Academic and Clinical Affairs and Professor of Radiology at Harvard Medical School, and is a member of the...
Roger Stupp, MD, Appointed Associate Director for Strategic Initiatives at Robert H. Lurie Cancer Center
Swiss neuro-oncologist Roger Stupp, MD, has been appointed Associate Director for Strategic Initiatives at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. A leading authority on the treatment of primary and metastatic brain cancer, Dr. Stupp will join Northwestern...
Expert Point of View: Olivier Michielin, MS, MD, PhD
Olivier Michielin, MS, MD, PhD, Head of Personalized Analytical Oncology and the Melanoma Clinic at Lausanne University Hospital in Switzerland, said the study was well designed, well conducted, and addressed an important clinical question “at the time of its inception.” But he agreed with Dr....
Study Looks for Optimal Dosing of Single-Agent Ipilimumab in Metastatic Melanoma
There has been debate as to the optimal dose of single-agent ipilimumab (Yervoy) in metastatic melanoma. A phase III study presented at the 2016 European Society for Medical Oncology (ESMO) Congress—the first to directly compare these doses—concluded that 10 mg/kg is more effective, but also more...
